Kibata M, Ishida M, Asano K, Uehara H, Saito K, Fuchimoto T, Ugaki K, Murakami H, Matoba K, Kotakemori Y, Shirai K, Yoshioka H, Nanba M, Yasuda M, Ishizaki M, Kitagawa N, Ikejiri K, Inohara R, Lee B J, Saino S, Sakado J, Matuzaka H, Numata K, Mandai M, Miyake K, Nakamura K
Atherosclerosis. 1980 Nov;37(3):333-42. doi: 10.1016/0021-9150(80)90137-9.
The effects of niceritrol, a nicotinic acid derivative, on the levels of HDL-cholesterol (HDL-Ch) and a mixture of VLDL- and LDL-Ch (VLDL- + LDL-Ch) were studied in hyperlipidemic patients. Serum total cholesterol (sTC) and serum triglyceride (sTG) were significantly reduced during niceritrol administration. Lipoprotein electrophoresis showed that niceritrol increased the alpha:beta ratio. HDL-Ch showed a significant increase of 12.5% by the 16th week of therapy. This increase was more marked in patients with lower pre-treatment HDL-Ch levels and significant in patients whose pre-treatment sTG levels were in excess of 200 mg/dl. Females displayed higher pre-treatment HDL-Ch levels (38.5 mg/dl) than males (30.6 mg/dl). However, niceritrol increased HDL-Ch significantly in both groups. At 16 weeks, the VLDL- + LDL-Ch level showed a significant decrease of 9.2%; the HDL-Ch:VLDL + LDL-Ch and HDL-CH:sTC ratios were significantly increased throughout niceritrol administration. Niceritrol is thought to be effective in preventing the development and progression of atherosclerosis because it raises the level of anti-atherogenic HDL-Ch and lowers the level of atherogenic VLDL- + LDL-Ch.
在高脂血症患者中研究了烟酸衍生物尼可占替诺对高密度脂蛋白胆固醇（HDL-Ch）以及极低密度脂蛋白和低密度脂蛋白胆固醇混合物（VLDL- + LDL-Ch）水平的影响。服用尼可占替诺期间，血清总胆固醇（sTC）和血清甘油三酯（sTG）显著降低。脂蛋白电泳显示尼可占替诺提高了α:β比值。到治疗第16周时，HDL-Ch显著升高了12.5%。这种升高在治疗前HDL-Ch水平较低的患者中更为明显，在治疗前sTG水平超过200mg/dl的患者中也很显著。女性治疗前HDL-Ch水平（38.5mg/dl）高于男性（30.6mg/dl）。然而，尼可占替诺在两组中均显著提高了HDL-Ch水平。在第16周时，VLDL- + LDL-Ch水平显著降低了9.2%；在整个尼可占替诺给药期间，HDL-Ch:VLDL + LDL-Ch和HDL-CH:sTC比值均显著升高。尼可占替诺被认为可有效预防动脉粥样硬化的发生和发展，因为它提高了抗动脉粥样硬化的HDL-Ch水平，并降低了致动脉粥样硬化的VLDL- + LDL-Ch水平。
